Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry

Abstract Aims To determine the characteristics of patients with coronary artery disease (CAD), peripheral artery disease (PAD), or both, initiating dual pathway inhibition (DPI) using rivaroxaban 2.5 mg twice daily plus aspirin, and to report their clinical outcomes and bleeding rates in clinical pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal. Cardiovascular pharmacotherapy 2022-12, Vol.8 (8), p.825-836
Hauptverfasser:	Fox, Keith A A, Aboyans, Victor, Debus, E Sebastian, Zeymer, Uwe, Cowie, Martin R, Patel, Manesh, Welsh, Robert C, Bosch, Jackie, Gay, Alain, Vogtländer, Kai, Anand, Sonia S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aspirin Aspirin - adverse effects Cardiac patients Cardiology Cardiovascular disease Clinical trials Comparative analysis Coronary Artery Disease - diagnosis Coronary Artery Disease - drug therapy Coronary Artery Disease - epidemiology Coronary heart disease Coronary vessels Factor Xa Inhibitors - adverse effects Female Hemorrhage - chemically induced Humans Life Sciences Male Medical research Medicine, Experimental Patient outcomes Peripheral Arterial Disease - diagnosis Peripheral Arterial Disease - drug therapy Peripheral Arterial Disease - epidemiology Pharmaceutical industry Registries Rivaroxaban Rivaroxaban - adverse effects Santé publique et épidémiologie Thrombosis Vein & artery diseases
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!